Source: Pharma Biz
BioMarin to buy Alesta Therapeutics to gain ALE1, a potential first oral therapy for hypophosphatasia
BioMarin Pharmaceutical Inc. announced that BioMarin has entered into a definitive agreement to acquire Alesta Therapeutics to gain Alesta's lead clinical─stage asset, ALE1.
Key Points
- BioMarin Pharmaceutical Inc. announced that BioMarin has entered into a definitive agreement to acquire Alesta Therapeutics to gain Alesta's lead clinical─stage asset, ALE1.
Published: August 20, 2026 3:30 am
Source: Pharma Biz